Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Jan

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care

Cancer Mortality According to Occupation in the United States

Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxane With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer

HER2-Positive Gastroesophageal Cancer Zanidatamab Plus Chemotherapy Prolongs Progression-Free Survival